` ALK B (ALK-Abello A/S) vs OMX Copenhagen 25 Comparison - Alpha Spread

ALK B
vs
OMX Copenhagen 25

Over the past 12 months, ALK B has significantly outperformed OMX Copenhagen 25, delivering a return of 10% compared to the OMX Copenhagen 25's 11% drop.

Stocks Performance
ALK B vs OMX Copenhagen 25

Loading
ALK B
OMX Copenhagen 25
Add Stock

Performance Gap
ALK B vs OMX Copenhagen 25

Loading
ALK B
OMX Copenhagen 25
Difference

Performance By Year
ALK B vs OMX Copenhagen 25

Loading
ALK B
OMX Copenhagen 25
Add Stock

Competitors Performance
ALK-Abello A/S vs Peers

OMX Copenhagen 25
ALK B
LLY
JNJ
NOVO B
ROG
Add Stock

ALK-Abello A/S
Glance View

Market Cap
37.9B DKK
Industry
Pharmaceuticals

ALK-Abelló A/S is a fascinating player in the global pharmaceutical market, renowned for its dedication to alleviating the impact of allergies through innovative treatments. Born in the heart of Denmark, this company has carved a niche for itself by focusing intensely on developing immunotherapy solutions for allergy sufferers—a sector often overshadowed by more glamorous pharmaceutical pursuits. ALK-Abelló operates at the forefront of the allergen immunotherapy landscape, committed to transforming the lives of those affected by allergic conditions, such as hay fever and allergic asthma. The company's portfolio includes allergy immunotherapy tablets, injection-based treatments, and diagnostic devices designed to offer comprehensive allergy solutions, catering to both established and emerging markets. The essence of ALK-Abelló’s business model lies in its strategic focus on the research, development, and commercialization of allergy immunotherapies. Through rigorous scientific research and development, the company has developed a series of groundbreaking allergy tablets that provide patients with a convenient, effective alternative to traditional injection-based treatments. This innovation not only harnesses scientific advancements but also addresses consumer demand for ease and efficacy. Revenue streams are predominantly generated through the sale of these innovative products to healthcare providers and patients, a process supported by strong partnerships with clinical professionals and an extensive distribution network. In essence, ALK-Abelló finds its competitive edge in delivering tailored, cutting-edge allergy treatments that not only improve patient outcomes but also promise to reduce the long-term economic burden of allergic diseases.

ALK B Intrinsic Value
182.37 DKK
Undervaluation 6%
Intrinsic Value
Price
Back to Top